Loading clinical trials...
Loading clinical trials...
BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Age
15 - 50 years
Sex
FEMALE
Healthy Volunteers
No
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
Wilmington, North Carolina, United States
Start Date
June 1, 2024
Primary Completion Date
March 31, 2035
Completion Date
March 31, 2035
Last Updated
February 27, 2026
728
ESTIMATED participants
No intervention
OTHER
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
CONTACT
1-877-411-4605briumvipregnancyregistry@ppd.comLead Sponsor
TG Therapeutics, Inc.
NCT07225504
NCT06276634
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192